Literature DB >> 16014946

Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Man Ki Song1, Christofer J Vindurampulle, Alejandra V E Capozzo, Jeffrey Ulmer, John M Polo, Marcela F Pasetti, Eileen M Barry, Myron M Levine.   

Abstract

Measles virus (MV) hemagglutinin (MV-H) and fusion (MV-F) proteins induce plaque reduction neutralizing (PRN) antibodies and cell-mediated immune responses that protect against clinical measles. DNA vaccines that encode MV-H and MV-F are being investigated as a new generation of measles vaccine to protect infants too young to receive currently licensed attenuated measles vaccines. However, it is unclear whether DNA vaccines encoding both MV-H and MV-F act synergistically to induce stronger immunity than immunization with plasmids encoding MV-H or MV-F alone. To address this question, we generated Sindbis virus-based pSINCP DNA vaccines that encode either MV-H or MV-F alone or bicistronic or fusion system vectors that encode both MV-H and MV-F (to mimic MV infection where both MV-H and MV-F proteins are expressed by the same mammalian cell). Mice immunized with DNA vaccine encoding MV-H alone developed significantly greater PRN titers than mice immunized with bicistronic constructs. Interestingly, the presence of MV-F in the bicistronic constructs stimulated serum MV-specific immunoglobulin G of reduced avidity. By contrast, mice immunized with bicistronic constructs induced equivalent or higher levels of MV-specific gamma interferon responses than mice immunized with DNA vaccine encoding MV-H alone. These data will help guide the design of DNA-based MV vaccines to be used early in life in a heterologous prime-boost strategy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014946      PMCID: PMC1181616          DOI: 10.1128/JVI.79.15.9854-9861.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Measles epidemic in Harare, Zimbabwe, despite high measles immunization coverage rates.

Authors:  R A Kambarami; K J Nathoo; F K Nkrumah; D J Pirie
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

3.  The 1st International Standard for anti-measles serum.

Authors:  T Forsey; A B Heath; P D Minor
Journal:  Biologicals       Date:  1991-07       Impact factor: 1.856

4.  Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines.

Authors:  V A de Souza; C S Pannuti; L M Sumita; H F de Andrade Júnior
Journal:  J Med Virol       Date:  1997-07       Impact factor: 2.327

5.  Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA.

Authors:  H L Davis; C L Millan; S C Watkins
Journal:  Gene Ther       Date:  1997-03       Impact factor: 5.250

Review 6.  Measles elimination in the Americas. Evolving strategies.

Authors:  C A de Quadros; J M Olivé; B S Hersh; M A Strassburg; D A Henderson; D Brandling-Bennett; G A Alleyne
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

7.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

8.  The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Authors:  H Peltola; O P Heinonen; M Valle; M Paunio; M Virtanen; V Karanko; K Cantell
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

9.  Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.

Authors:  G Alkhatib; J Roder; C Richardson; D Briedis; R Weinberg; D Smith; J Taylor; E Paoletti; S H Shen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.

Authors:  D Naniche; G Varior-Krishnan; F Cervoni; T F Wild; B Rossi; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more
  7 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model.

Authors:  Yuan Qi; Kailin Xing; Lanlin Zhang; Fangyu Zhao; Ming Yao; Aiqun Hu; Xianghua Wu
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-06       Impact factor: 4.553

3.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

4.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

5.  Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity.

Authors:  Marcela F Pasetti; Karina Ramirez; Aldo Resendiz-Albor; Jeffrey Ulmer; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

6.  Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.

Authors:  Ianko D Iankov; Alan R Penheiter; Guy E Griesmann; Stephanie K Carlson; Mark J Federspiel; Evanthia Galanis
Journal:  Virus Res       Date:  2012-12-21       Impact factor: 3.303

7.  Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Authors:  Ianko D Iankov; Mark J Federspiel; Evanthia Galanis
Journal:  Vaccine       Date:  2013-08-12       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.